Disease: Respiratory syncytial virus infection

Vera-Punzano

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Maglione

Italy
|
2023-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Santus

Italy
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

Calomfirescu-Avramescu

Romania
|
2022-2024
  • Infants (<1 year)
  • Fragile population
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Palivizumab

Perramon-Malavez

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

SIREN Winter Pressures sub-study

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Healthcare workers
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus

Costantino

Italy
|
2022-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Coma 2

Spain
|
2023-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • Primary care
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Coma

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Primary care
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Ocana de Sentuary

France
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Ezpeleta

Spain
|
2023-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

RAPID

The Netherlands
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • Respiratory syncytial virus